FIGNL1 and cancer: The ATPase dead mutant of FIGNL1 is still able to dissociate RAD51 from ssDNA in vitro and may not be an effective therapeutic approach49, however, disruption of the interaction between FLIP and FIGNL1 using small peptides might be a potent strategy for treatment of various cancers.